© Reuters
Shares of Aurinia Prescription drugs (NASDAQ: NASDAQ:) noticed a notable improve at this time, rising by 6.7% amid hypothesis a few potential acquisition by Gilead Sciences (NASDAQ:). The rumors have been sparked by the sighting of a Gilead jet on the Edmonton headquarters of Aurinia, suggesting that discussions is likely to be underway. This comes after Aurinia’s announcement in June about exploring strategic options.
Buyers and analysts are carefully watching the scenario, with RBC Capital Markets weighing in on the attainable sale value. This potential buyout has been a topic of curiosity since October 2021, when Bristol-Myers Squibb (NYSE:)’s prior curiosity in Aurinia got here to gentle, fueling ongoing hypothesis throughout the market.
This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.